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ABSTRACT:
Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by 
short median survival despite intensive therapies. The clinical behavior of MCL most 
likely relates to the complex pathophysiology of the disease which includes its genetic 
hallmark, the chromosomal translocation t(11;14) resulting in aberrant expression 
of cyclin D1, alteration in the DNA damage response, and constitutive activation of 
key antiapoptotic pathways such as phosphatidyl-inositol 3-kinase (PI3K)/Akt and 
nuclear factor-kB (NF-kB). Together, these changes result in cell cycle dysregulation 
and give rise to profound genetic instability. Given this complex pathophysiology, the 
limited number of options for patients with relapsed/refractory MCL, and the difficulty 
in achieving long-lasting remissions with conventional approaches, it is essential to 
explore new treatment options targeting the pathophysiology of MCL. We have recently 
reported that milatuzumab, a fully humanized anti-CD74 monoclonal antibody (mAb), 
in combination with anti-CD20 mAbs has significant preclinical and clinical activity 
in MCL. Here we discuss these results, provide additional insights into milatuzumab-
mediated MCL cell death, and report preliminary data on the activity of other targeted 
biologic agents including PCI-32765, CAL-101 and mammalian target of rapamycin 
(mTOR) inhibitors currently undergoing evaluation at our institution and others. 
INTRODUCTION
Mantle cell lymphoma (MCL) is a neoplasm 
classified as an aggressive B-cell malignancy [1]  that 
accounts for approximately 3 to 8% of Non-Hodgkin’s 
lymphoma (NHL) cases diagnosed annually [2-4]. MCL 
patients are typically diagnosed at age 60 to 65 years, and 
present  with  generalized  non-bulky  lymphadenopathy 
and frequent extranodal disease burden [5]. While some 
patients  present  with  indolent  disease,  most  have  a 
more aggressive disease course, and virtually all MCL 
patients require systemic therapy [6-12]. Median overall 
survival (OS) of MCL patients has been reported to be 
approximately three years [4, 5]; however recent series 
have shown an (OS) of 5 to 7 years [13, 14]. Aggressive 
therapies including chemo-immunotherapy [8, 15] or high 
dose  chemotherapy  followed  by  autologous  stem  cell 
transplant [16, 17] have been shown to improve outcome; 
however, no standard therapy offers the potential for cure. 
The high response rate (RR) and longer progression free 
survival (PFS) obtained with these regimens certainly 
represent a major advance. However, several challenges 
remain in the care of patients with MCL including the 
absence of curative therapy, associated major toxicities, 
and the limited number of treatment options for patients 
with relapsed/refractory disease [18]. 
The pathobiology of MCL is complex and includes 
alterations in the cell cycle as a consequence of cyclin D1 
over-expression driven by the chromosomal translocation 
t(11;14)(q13;q32)  [19],  abnormalities  in  the  DNA 
damage response [20], and constitutive activation of key 
antiapoptotic pathways including phosphatidyl-inositol 
3-kinase (PI3K)/Akt and nuclear factor-kB (NF-kB) [21, 
22]. This biologic complexity may explain the natural 
history of MCL which is characterized by a course of 
increasingly short-lived progressive relapses [23]. Novel 
treatment approaches targeting MCL pathobiology are 
therefore essential. 
Monoclonal  antibodies  (mAbs)  targeting  surface 
proteins and tumor cell survival pathways have become 
widely adopted in the treatment of patients with lymphoma 
for a variety of reasons.  These include improvement of 
patient outcomes when combined with chemotherapy and Oncotarget 2012; 3:  203-211 204 www.impactjournals.com/oncotarget
limited toxicity profiles, making mAbs ideal alternative 
options  for  heavily  pretreated  patients  with  relapsed/
refractory disease [24]. Rituximab (Genentech Inc, San 
Francisco, CA), a chimeric anti-human CD20 mAb, has 
been widely utilized to treat MCL patients [25, 26]. As 
a single agent, rituximab has been tested in untreated as 
well as pretreated patients with RR of approximately 30% 
and a median response duration of 6 months [25, 27]. In 
combination with anthracycline-based regimens, rituximab 
significantly improved RR and time to progression of 
MCL patients when compared to patients treated with 
chemotherapy alone [28]. Furthermore, a recent meta-
analysis of seven randomized controlled trials indicated 
that rituximab plus chemotherapy may prolong OS in MCL 
as compared to chemotherapy alone [8]. The promising 
results from several clinical trials support the concept of 
combining mAbs to target multiple pathways in NHLs [29, 
30]. Dual antibody therapy offers several advantages over 
a single mAb approach including potentially enhanced 
activity when compared to single mAb or chemotherapy 
approachs due to alternative mechanisms of action, lack 
of significant hematologic toxicities, ability to overcome 
single-agent  resistance  mechanisms,  and  improved 
tolerance in heavily pre-treated, older patients or patients 
with significant comorbidities. 
Milatuzumab (hLL1, IMMU-115, Immunomedics 
Inc., Morris Plains, NJ) is a fully humanized mAb specific 
for CD74 [31], a type II transmembrane glycoprotein 
associated with MHC class II that was recently found to 
play an important role in the maturation and proliferation 
of  B-cells  by  activating  the  PI3K/Akt  and  the  NF-қß 
pathways [32, 33]. CD74 is expressed on the majority of 
B-cell malignancies including MCL [34], making it an 
attractive therapeutic target. Milatuzumab demonstrated 
anti-proliferative  activity  in  transformed  B-cell  lines 
and improved survival in preclinical models [33, 35]. 
Unlike  rituximab,  milatuzumab  mainly  causes  direct 
cytotoxicity with little or no role for antibody dependent 
cell-mediated  cytotoxicity  (ADCC)  or  complement-
dependent cytotoxicity (CDC) [35, 36]. Phase I testing in 
multiple myeloma demonstrated that milatuzumab is well-
tolerated [37] and is presently being evaluated in phase 
I/II clinical trials for the treatment of NHL and chronic 
lymphocytic leukemia (NCT00868478; NCT00603668; 
NCT00504972).
We  recently  reported  that  the  combination  of 
milatuzumab  and  rituximab  has  preclinical  in vitro 
and in vivo activity in MCL [34], with the combination 
approach being justified by the fact that these two mAbs 
target distinct antigens lacking known association and, 
as  single  agents,  have  demonstrated  substantial  anti-
tumor activity in B cell non-Hodgkin’s lymphoma (NHL) 
cells [35, 36]. Treatment of MCL cell lines and primary 
patient tumor cells with either immobilized milatuzumab 
or rituximab resulted in statistically significant enhanced 
cell death, which was further potentiated when the two 
mAbs were combined. We found that this combination 
mAb  treatment  induced  a  caspase-independent  non-
classical apoptotic, non-autophagic cell death pathway. 
Furthermore, milatuzumab- and rituximab-induced cell 
death was mediated by radical oxygen species (ROS) 
generation and loss of mitochondrial membrane potential. 
We also highlighted the importance of actin dynamics 
and disruption of the NF-κB pathway in milatuzumab- 
and rituximab-mediated cell death. While it is known 
that  mAbs  directed  to  CD20  and  HLA-DR  can  elicit 
lysosome-mediated  cell  death  [38,  39],  we  recently 
showed that milatuzumab also has the ability to induce 
lysosomal membrane permeabilization (LMP) (Alinari 
L and Baiocchi RA, unpublished data). Acridine orange 
(AO) at acidic pH (for example in lysosomes) fluoresces 
red, and when AO leaks into a neutral pH (for example 
in cytosol) it causes an increase in green fluorescence 
which was detected in milatuzumab treated MCL cells 
by flow cytometry. LMP is a well established mechanism 
of cell death [40] which happens as a consequence of the 
translocation of lysosomal hydrolases (such as cathepsin) 
from the lysosomal compartment to the cytosol. It remains 
to be clarified if ROS generation and loss of mitochondrial 
membrane  potential  are  the  triggers  or  occur  as  a 
consequence of LMP in milatuzumab-treated MCL cells. 
We  have  also  shown  that  FTY720,  an 
immunosuppressive  agent  recently  approved  by  the 
FDA  for  the  treatment  of  relapsed  multiple  sclerosis 
[41], has significant in vitro activity in MCL, promoting 
MCL  cell  death  through  caspase-independent  ROS 
generation and down-modulation of p-Akt and Cyclin 
D1, with subsequent accumulation of cells in G0/G1 and 
G2/M phases of the cell cycle [42]. We recently further 
elucidated the mechanism of action of FTY720 in MCL 
cell lines and showed that FTY720 treatment of MCL cells 
leads to autophagy blockage and LMP with subsequent 
translocation of lysosomal hydrolases in the cytosol [43]. 
FTY720 treatment of MCL cells led to increase CD74 
expression by preventing its degradation in the lysosomal 
compartment  demonstrating  for  the  first  time  that  a 
druggable target can be induced by autophagy blockade. 
The combination of FTY720 and milatuzumab resulted 
in statistically significant enhanced cell death in vitro 
and significantly prolonged survival in a mouse model of 
human MCL. The most clinically relevant aspects of these 
findings are: 1) we were able to significantly increase the 
level of a “druggable” target (CD74) using an active anti-
MCL agent (FTY720), generating more CD74 available 
for milatuzumab binding, and  2) because of the FTY720 
effect on CD74 expression, we were able to significantly 
decrease the dose of these two agents without affecting the 
synergistic effect on MCL cell viability, suggesting that 
lower dosages may be used in vivo resulting in a more 
favorable toxicity profile. 
The  primary  toxicity  of  FTY720  is 
immunosuppression, which occurs via interaction with Oncotarget 2012; 3:  203-211 205 www.impactjournals.com/oncotarget
sphingosine  1-phosphate  (S1P)  receptors  [41].  OSU-
2S, a non-phosphorylatable FTY720 derivative recently 
developed at the Ohio State University [44] has similar 
cytotoxic activity in MCL cell lines, suggesting that the 
S1P  signaling  is  not  necessary  for  FTY720-mediated 
anti-tumor effect. Considering that OSU-2S is predicted 
to have less immunosuppressive effects as compared to 
FTY720, this compound may provide anti-tumor activity 
without the S1P-mediated immune suppressive properties.   
More studies are needed to fully characterize the immune 
modulatory and anti-tumor activity properties of OSU-2S.   
In an attempt to increase the activity of a combined 
mAbs approach, we also tested two novel humanized anti-
CD20 antibodies, veltuzumab (Immunomedics Inc.) and 
ofatumomab (Genmab Inc, Princeton NJ), and showed that 
the combination of milatuzumab with either veltuzumab 
or ofatumomab resulted in enhanced cell death compared 
to  either  agent  alone  [34]. Veltuzumab,  which  differs 
from rituximab due to an amino acid substitution in the 
compliment binding region of the variable heavy chain 
of CDR3, was designed to limit infusion reactions and 
reduce infusion times as compared to rituximab [45]. 
However, it has been reported that veltuzumab has several 
additional advantages over rituximab including improved 
CDC with equal rates of ADCC, slower off-rates, shorter 
infusion times, higher potency, and improved therapeutic 
responses in animal models [46]. Phase II clinical testing 
of  veltuzumab  demonstrated  single  agent  activity  in 
patients with relapsed and refractory NHL [47]. As a 
result  of  the  anti-tumor  activity  we  observed  in vitro 
with combined veltuzumab and milatuzumab [34], and 
the promising preliminary results obtained with single 
agent veltuzumab in NHL patients [47, 48], we initiated 
a phase I/II trial testing the combination of milatuzumab 
and veltuzumab in patients with relapsed or refractory 
B-cell NHL (NCT00989586) at the Ohio State University 
[49]. Patients received veltuzumab 200 at mg/m2 weekly 
combined with escalating doses of milatuzumab at 8, 16, 
and 20 mg/kg twice per week of weeks one through four 
(induction), and weeks twelve, twenty, twenty-eight, and 
thirty-six (extended induction). The dosing schedule for 
this combination trial is based on the extended induction 
rituximab  schedule  used  by  Ghielmini  and  the  Swiss 
Group for Clinical Cancer Research (SAAK) investigators 
[50, 51] and this dosing schedule has been adopted by 
the  Alliance  (formerly  Cancer  and  Leukemia  Group 
B) Cooperative Group as the backbone for studies of 
combined mAbs [52]. All patients received pre-medication 
with acetominophen, diphenhydramine, and famotidine 
prior  to  each  veltuzumab  dose  and  acetominophen, 
diphenhydramine, and hydrocortisone before and after 
each milatuzumab dose. In the first two cohorts of the 
phase I study, three of six patients experienced grade 3 
infusion reactions during or immediately following the 
milatuzumab  infusion.  Due  to  the  observed  infusion 
reactions with milatuzumab, the protocol was amended 
to  include  additional  premedication  with  intravenous 
antihistamine, and dexamethasone 20 mg pre-milatuzumab 
and 10 mg post-milatuzumab. The schedule of treatment 
was also modified so that the antibodies were no longer 
administered on the same day and milatuzumab was given 
once weekly. Following the modification to the protocol, 
no further grade 3 infusion reactions were observed. In 
the phase I study, at the time of last reporting, eighteen 
patients were enrolled and had completed at least four 
weeks  of  combined  veltuzumab  and  milatuzumab. 
Histologies  included  follicular  NHL  grade  1-2  (n=5), 
grade 3 (n=5), transformed follicular (n=1), diffuse large 
B-cell lymphoma (n=4), marginal zone lymphoma (n=1), 
MCL (n=1), and lymphoplasmacytic lymphoma (n=1).   
Median age was 65 years (range 44-81), and patients 
received a median of 3 prior therapies (range 1 – 9), 
including 3 patients who had undergone prior autologous 
stem  cell  transplant.  Ten  of  18  (56%)  patients  were 
refractory to rituximab defined as having less than a partial 
response to the last rituximab-containing regimen.  Other 
grade 3-4 toxicities at least possibly related to protocol 
therapy consisted of lymphopenia (n=10, 56%), fatigue 
(n=2,  11%),  neutropenia  (n=2,  11%),  hyperglycemia 
(n=1,  6%),  hypoklemia  (n=1,  6%),  and  anemia  (n=1, 
6%).  Grade 1-2 infections (n=5, 27%) included thrush, 
sinusitis, and pneumonia with no patients requiring dose 
delays  or  hospitalization.    Other  frequently  observed 
grade 1-2 toxicities were transient hyperglycemia (n=12, 
66%), thrombocytopenia (n=11, 61%), reversible infusion 
reactions (n=9, 50%), and fatigue (n=8, 44%). Human anti-
veltuzumab and anti-milatuzumab antibodies, collected 
pretreatment and day 1 of weeks 4, 12, and 36, have not 
been detected in any patient. To date, complete responses 
were observed in 2 patients including one with grade 1-2 
follicular NHL (3 prior therapies) who was rituximab-
refractory and ultimately underwent allogeneic transplant 
and one with marginal zone lymphoma (1 prior therapy). 
Partial responses were observed in 2 patients; one with 
grade 3 follicular NHL refractory to rituximab with 3 
prior therapies including autologous transplant and one 
patient who had received 5 prior therapies.  All responding 
patients achieved response following induction therapy.   
Stable disease (SD) was observed in 10 patients including 
1 patient with MCL of a median duration of 5.25 months 
to date (range 2.5-12 months) and 2 patients remain on 
protocol therapy.  Combination therapy with veltuzumab 
and milatuzumab was well-tolerated in a population of 
heavily pre-treated patients with relapsed or refractory 
NHL, 22% having an objective overall response, including 
rituximab-refractory patients.  Enrollment in the phase II 
study of selected NHL subtypes including indolent NHL 
and MCL is ongoing.  Oncotarget 2012; 3:  203-211 206 www.impactjournals.com/oncotarget
NOVEL BIOLOGIC AGENTS FOR 
TREATMENT OF MCL
 In addition to the ongoing evaluation of monoclonal 
antibody therapy in relapsed or refractory MCL, several 
targeted biologic agents are undergoing preclinical and 
clinical evaluation at our institution and others have shown 
early promise as effective therapeutic agents in MCL.  
PCI-32765  is  an  orally  bioavailable  inhibitor  of 
Bruton’s tyrosine kinase (BTK), which is a key component 
of the B-cell receptor signaling pathway [53]. It selectively 
and permanently inhibits BTK, resulting in inhibition of 
B-cell activation and downstream signaling of the B-cell 
receptor [54]. Preclinical testing in canine B-cell NHL 
resulted in objective responses [54]. Preclinical evaluation 
in chronic lymphocytic leukemia (CLL) demonstrated 
that in vitro, PCI-32765 induced apoptosis in CLL cells 
via a caspase-dependent mechanism as well as inhibited 
activation-induced CLL cell proliferation [55]. PCI-32765 
demonstrated clinical responses with minimal toxicity 
in the phase I study in relapsed and refractory B-cell 
malignancies [56]. The objective RR was 43% for 47 
patients enrolled. A total of four patients with MCL were 
enrolled and three of four achieved an objective response, 
with all three patients remaining on study for greater 
than 6 months.  Grade 3 or higher toxicities occurred in 
19% of patients and included grade 3 neutropenia. The 
preliminary results of the ongoing phase II study of PCI-
32765 were recently reported [57]. A total of 48 patients 
with MCL were enrolled, in cohorts of bortezomib-naïve 
and bortezomib-exposed, with 24 patients evaluable for 
response.  The median age was 67 years (range 62-72) and 
the median number of prior therapies was 2 (range 1-5) 
including 5 patients (13%) who had undergone prior stem 
cell transplant.  Patients received continuous daily dosing 
of 560 mg orally of PCI-32765. The ORR for both cohorts 
was 67% (16/24); ORR is 58% (7/12) in the bortezomib-
naive cohort and 75% (9/12) in the bortezomib-exposed 
cohort.  Treatment  was  well-tolerated  with  the  most 
frequent grade 1-2 toxicities including fatigue, diarrhea, 
and  nausea.    PCI-32765  is  currently  undergoing 
evaluation both as a single agent and in combination with 
immuno-chemotherapy  in  relapsed  or  refractory  MCL 
(NCT012363910) and B-cell NHL (NCT00849654 and 
NCT01109069) at our institution and others. 
The  phosphatidylinositol  3-kinase  (PI3K)/AKT 
pathway is central to the survival of several different 
B-cell NHL histologies including MCL and therefore may 
represent an attractive therapeutic target [58-60]. AKT 
is a serine threonine kinase that regulates cell survival, 
proliferation, and apoptosis, in NHL [61]. Constitutive 
activation of AKT has been shown to be essential to the 
pathogenesis and survival of MCL [21, 62, 63]. In vitro 
testing of MCL cell lines with AKT inhibitors including 
LY294002 and wortmannin resulted in apoptosis via a 
caspase-dependent mechanism [21, 64]. However a phase 
II testing of ezastaurin, an oral serine/threonine kinase 
inhibitor which suppresses signaling through the PI3K/
AKT pathway, in relapsed and refractory MCL resulted in 
modest clinical activity [65]. 
CAL-101 is an oral p110δ selective PI3K inhibitor 
[66]. Inhibition of the PI3K pathway with CAL-101 in a 
variety of hematologic malignancies in vitro resulted in 
apoptosis associated with a decrease in phosphorylated 
AKT (p-AKT) levels and other downstream targets such 
as p-S6 and GSk3-β [66]. In another recent preclinical 
evaluation,  CAL-101  treatment  resulted  in  caspase-
dependent apoptosis of CLL cells [67]. Importantly, CAL-
101 treatment did not result in apoptosis of normal T-cell 
or NK-cells, and did not affect antibody-dependent cellular 
cytotoxicity when combined with mAbs such as rituximab. 
Additionally,  CAL-101  inhibited  the  production  of 
proinflammatory/prosurvival cytokines by T-cells and NK-
cells including IL-6, IL-10, TNF-α, and INF-γ, suggesting 
that blocking production of these cytokines in vivo would 
potentially have the effect of antagonizing their survival 
effects  on  CLL  cells.  Furthermore,  the  investigators 
postulate that CAL-101 may abrogate infusional toxicity 
seen  with  mAb  therapy  such  as  rituximab  through 
decreased production of these cytokines. 
The promising preclinical data supported clinical 
development of this agent. In the ongoing phase I clinical 
trial  with  CAL-101  (NCT00710528,  NCT01090414) 
in  patients  with  relapsed  and  refractory  hematologic 
malignancies, responses were observed at all dose levels. 
At the time of last reporting, 55 patients with B-cell NHL 
had enrolled (28 patients had indolent NHL: follicular 
lymphoma  n=15,  small  lymphocytic  lymphoma  n=6, 
Waldenstrom’s  macroglobulinemia n=4, marginal  zone 
lymphoma n=3; 27 had aggressive NHL: MCL (n=18), 
diffuse large B-cell lymphoma (n=9). Approximately half 
of the patients had refractory disease with a median of 5 
prior regimens. Dose levels ranged from 50 mg to 350 
mg orally twice daily. The primary observed dose limiting 
toxicities were reversible liver function test abnormalities.   
Hematologic toxicity was infrequent. The overall response 
rate was 62% (10 out of the 16 evaluable MCL patients), 
with a median duration of response of 3 months (range 
1-8) [68].  
Given the central role of the PI3K/AKT pathway 
in  NHL  [69-71],  downstream  targets  such  as  mTOR 
represent  another  promising  therapeutic  target  [21]. 
Several mTOR inhibitors have been evaluated in relapsed 
and refractory MCL, and temsirolimus and everolimus 
have been studied most extensively [72-76]. The initial 
phase II study of temsirolimus in relapsed and refractory 
mantle  cell  lymphoma  utilized  a  dose  of  250  mg 
intravenously, administered weekly [73].  The ORR was 
34% with a median time to progression of 6.5 months.   
The primary toxicities observed were myelosuppression, 
mucositis,  fatigue,  hyperglycemia,  infections,  and 
hypertriglyceridemia [73].  Due to the observed toxicities Oncotarget 2012; 3:  203-211 207 www.impactjournals.com/oncotarget
and frequent need for dose reductions, a phase II study 
of 25 mg weekly of temsirolimus was performed.  The 
ORR was 41% with a median time to progression of 6 
months.    The  authors  concluded  that  the  lower  dose 
retained similar activity but was better tolerated with less 
myelosuppression [74].  A phase III open label study of 
temsirolimus  administered  on  a  scheduled  of  175  mg 
weekly followed by either 75 mg or 25 mg weekly was 
compared to investigator’s choice in patients with relapsed 
or refractory MCL.  The median PFS was 4.8 months, 3.4 
months, and 1.9 months for temsirolimus 175/75 mg, 
175/25 mg, and investigator’s choice, respectively.  The 
ORR for temsiroliumus 175/75 mg was 22%, and the 
primary adverse events were asthenia and hematologic 
toxicities [75].  In a promising phase II study, temsirolimus 
was combined with rituximab in patients with relapsed 
and  refractory  MCL.    The  dosing  schedule  included 
temsirolimus 25 mg weekly and rituximab 375 mg/m2 
weekly for 4 weeks and then every other month for up 
to 12 cycles.  The ORR was 59%; for rituximab-sensitive 
patients the ORR was 63%, and for rituximab-refractory 
patients the ORR was 52% [77]. Everolimus is an orally 
bioavailable mTOR inhibitor which demonstrated anti-
tumor  activity  in  several  histologic  subtypes  of  NHL 
including MCL [73]. A phase II study of everolimus 10 
mg daily in patients with relapsed and refractory MCL 
demonstrated an ORR of 20% with an additional 49% 
patients experiencing stable disease. Median progression 
free  survival  was  5.5  months.  The  primary  observed 
toxicities  were  hematologic  in  nature  [76].  Similar 
findings were observed in a phase II study of everolimus 
in patients with relapsed aggressive lymphomas where the 
ORR was 30% and 6 of 19 (32%) patients with MCL had 
an objective response [73]. Currently, studies are ongoing 
evaluating this class of drugs in MCL as single agents, in 
combination with chemotherapy, and in combination with 
other targeted therapies.  
In  summary,  MCL  is  an  aggressive  B-cell 
malignancy which is incurable with standard therapies.   
While the response rate to initial therapy is high, patients 
invariably relapse, with a tendency toward lower response 
rates and shorter duration of remissions with subsequent 
therapies.  Our  group  has  demonstrated  preclinical  in 
vitro and in vivo activity in MCL with the combination of 
milatuzumab and anti-CD20 mAbs and milatuzumab with 
FTY720. Currently, phase I/II testing of the combination 
milatuzumab and veltuzumab in patients with relapsed 
and refractory B-cell NHL is ongoing.  Initial toxicity 
data from phase I study has been primarily related to 
reversible infusion reactions. Preliminary activity data 
from the first patients enrolled in the phase I study has 
been encouraging with four of eighteen heavily pretreated 
patients  responding,  although  several  different  NHL 
histology were included. Other potentially effective novel 
therapies  for  MCL  actively  undergoing  investigation 
include the Bruton’s tyrosine kinase inhibitor, PCI-32765, 
mTOR inhibitors such as temsirolimus and everolimus, 
and the PI3 kinase inhibitor, CAL-101.  Future directions 
in the treatment of MCL include combinations of mAbs, 
targeted biologic agents, and cytotoxic chemotherapy.  
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